501 related articles for article (PubMed ID: 8712750)
1. Evaluation of CYFRA 21-1 in malignant and benign pleural effusions.
Toumbis M; Rasidakis A; Passalidou E; Kalomenidis J; Alchanatis M; Orphanidou D; Jordanoglou J
Anticancer Res; 1996; 16(4A):2101-4. PubMed ID: 8712750
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions.
Miédougé M; Rouzaud P; Salama G; Pujazon MC; Vincent C; Mauduyt MA; Reyre J; Carles P; Serre G
Br J Cancer; 1999 Nov; 81(6):1059-65. PubMed ID: 10576665
[TBL] [Abstract][Full Text] [Related]
3. Preliminary evaluation of the new tumor marker, CYFRA 21-1, in lung cancer patients.
Koga H; Eguchi K; Shinkai T; Tamura T; Ohe Y; Oshita F; Saijo N; Kondo H; Oki K; Okura H
Jpn J Clin Oncol; 1994 Oct; 24(5):263-8. PubMed ID: 7526016
[TBL] [Abstract][Full Text] [Related]
4. [Diagnostic value of the combined determination of carcinoembryonic antigen (CEA) in pleural effusion and serum with an enzyme immunoassay (EIA). Sensitivity, specificity and relation to tumor type].
Klech H; Rona G; Hutter C; Bayer PM; Kummer F
Wien Klin Wochenschr; 1986 Sep; 98(17):564-73. PubMed ID: 3020811
[TBL] [Abstract][Full Text] [Related]
5. [Cyfra 21-1--a new tumor marker of the cytokeratin series in differential diagnosis of lung diseases].
Oremek GM; Seiffert UB; Siekmeier R; Kirsten R
Med Klin (Munich); 1995 Jan; 90(1):23-6. PubMed ID: 7533887
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Cyfra 21-1 as a marker for lung cancer.
Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
[TBL] [Abstract][Full Text] [Related]
7. Serum tumor marker CYFRA 21-1 in the diagnostics of NSCLC lung cancer.
Pavićević R; Milicić J; Bubanović G; Supe S
Coll Antropol; 1998 Dec; 22(2):629-35. PubMed ID: 9887620
[TBL] [Abstract][Full Text] [Related]
8. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
[TBL] [Abstract][Full Text] [Related]
9. [Clinical usefulness of serum assay of EIA-CYFRA 21-1 in lung cancer].
Satoh H; Yagyu H; Sumi M; Ishikawa H; Hamada M; Suyama T; Naitoh T; Inoue M; Saitoh T; Uchida Y
Gan To Kagaku Ryoho; 1994 May; 21(6):795-9. PubMed ID: 7514388
[TBL] [Abstract][Full Text] [Related]
10. Serum and tissue distribution of a fragment of cytokeratin 19 (cyfra 21-1) in lung cancer patients.
Quillien V; Ramee MP; Bansard JY; Meritte H; Briens E; Logeais Y; Langanay T; Corbineau H; Dazord L
Anticancer Res; 1995; 15(6B):2857-63. PubMed ID: 8669879
[TBL] [Abstract][Full Text] [Related]
11. CYFRA 21-1 in non-small cell lung cancer--standardisation and application during diagnosis.
Pavićević R; Bubanović G; Franjević A; Stancić-Rokotov D; Samarzija M
Coll Antropol; 2008 Jun; 32(2):485-98. PubMed ID: 18756899
[TBL] [Abstract][Full Text] [Related]
12. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of Her-2/neu, Cyfra 21-1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma.
Huang WW; Tsao SM; Lai CL; Su CC; Tseng CE
Pathology; 2010 Apr; 42(3):224-8. PubMed ID: 20350214
[TBL] [Abstract][Full Text] [Related]
14. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].
Li R; Li R; Wang Y
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296
[TBL] [Abstract][Full Text] [Related]
15. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
[TBL] [Abstract][Full Text] [Related]
16. Utility of serum cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA) as tumour markers for non-small cell lung cancer.
Chantapet P; Riantawan P; Lebnak P; Getngern P
J Med Assoc Thai; 2000 Apr; 83(4):383-91. PubMed ID: 10808698
[TBL] [Abstract][Full Text] [Related]
17. Serum tumor marker CYFRA 21-1 in the diagnostics of squamous cell lung cancer--comparison with CEA.
Berzinec P; Zuffová H; Letkovicová M; Arpásová M
Neoplasma; 1996; 43(3):159-61. PubMed ID: 8841502
[TBL] [Abstract][Full Text] [Related]
18. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
19. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
[TBL] [Abstract][Full Text] [Related]
20. Carcinoembryonic antigen (CEA) levels in pleural effusions and sera of lung cancer patients.
Ogushi F; Fukuoka M; Takada M; Tamai S; Sakai N; Negoro S; Okunaka N; Sone S; Tsubura E
Jpn J Clin Oncol; 1984 Sep; 14(3):321-7. PubMed ID: 6090732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]